Fig. 1From: The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical studyThe CONSORT diagram. Patients were randomised to low (LD, 100 μg), medium (MD, 300 μg) or high dose (HD, 900 μg) with GM-CSF or Alhydrogel as adjuvantBack to article page